907 results match your criteria Pityriasis Rubra Pilaris


A case of refractory type I pityriasis rubra pilaris treated with tildrakizumab.

Clin Exp Dermatol 2021 Jun 8. Epub 2021 Jun 8.

Dermatology Unit, Department of Mentals and Physical Health and Preventive medicine, University of Campania Luigi Vanvitelli Naples, Italy.

Pityriasis rubra pilaris (PRP) is a rare chronic erythematous squamous disorder of unknown etiology . To our knowledge, we report the first case of PRP resistant to conventional therapies that was successfully treated with tildrakizumab, an interleukin-23 inhibitor. A 55-year-old man came to our department due to the presence of severe, generalized erythematous and scaly eruption that started six weeks earlier on the scalp and spread rapidly. Read More

View Article and Full-Text PDF

CARD14-associated papulosquamous eruption (CAPE) in a toddler responding to treatment with acitretin.

Pediatr Dermatol 2021 Jun 2. Epub 2021 Jun 2.

Paediatrics Academic Clinical Programme, SingHealth Duke-NUS Graduate Medical School, Singapore, Singapore.

CARD14-associated papulosquamous eruption (CAPE) is a rare autosomal dominant dermatosis that presents classically in early childhood with clinical features of both psoriasis and pityriasis rubra pilaris (PRP). The disease is known to be refractory to topical and systemic therapies classically used for psoriasis, with the majority of reported cases requiring treatment with biologics, such as ustekinumab and secukinumab. We present a toddler with a clinical presentation consistent with CAPE and found to have a novel heterozygous variant of the CARD14 gene. Read More

View Article and Full-Text PDF

Acute postinfectious pityriasis rubra pilaris as a cutaneous manifestation in COVID-19: a case report and its dermoscopic features.

J Eur Acad Dermatol Venereol 2021 May 31. Epub 2021 May 31.

Department of Dermatology, Venereology and Allergology, Faculty of Medicine, Medical University of Gdańsk, Gdańsk, Poland.

View Article and Full-Text PDF

Acute Postinfection Pityriasis Rubra Pilaris: Excellent Response to Emollients and Topical Corticosteroids.

Actas Dermosifiliogr 2021 May 11. Epub 2021 May 11.

Departamento de Dermatología, Facultad de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile. Electronic address:

View Article and Full-Text PDF

A case of recurrent and paraneoplastic pityriasis rubra pilaris.

JAAD Case Rep 2021 Jun 29;12:74-76. Epub 2021 Apr 29.

Department of Dermatology, University of Michigan Medical School, Ann Arbor, Michigan.

View Article and Full-Text PDF

A case of treatment-resistant pityriasis rubra pilaris responsive to secukinumab.

Australas J Dermatol 2021 May 24. Epub 2021 May 24.

University of Melbourne, Parkville, Victoria, Australia.

View Article and Full-Text PDF

Altered replication stress response due to CARD14 mutations promotes recombination-induced revertant mosaicism.

Am J Hum Genet 2021 Jun 17;108(6):1026-1039. Epub 2021 May 17.

Department of Dermatology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Hokkaido 060-8638, Japan; Department of Dermatology, Faculty of Medicine, University of Tsukuba, Tsukuba 305-8575, Japan. Electronic address:

Revertant mosaicism, or "natural gene therapy," refers to the spontaneous in vivo reversion of an inherited mutation in a somatic cell. Only approximately 50 human genetic disorders exhibit revertant mosaicism, implicating a distinctive role played by mutant proteins in somatic correction of a pathogenic germline mutation. However, the process by which mutant proteins induce somatic genetic reversion in these diseases remains unknown. Read More

View Article and Full-Text PDF

Facial Discoid Dermatosis: A New Variant of Pityriasis Rubra Pilaris?

Actas Dermosifiliogr (Engl Ed) 2021 May 13. Epub 2021 May 13.

Servicio de Dermatología. Hospital do Meixoeiro, EOXI, Vigo, Spain.

View Article and Full-Text PDF

Treatment of pityriasis rubra pilaris with risankizumab in two cases.

J Dtsch Dermatol Ges 2021 May 10. Epub 2021 May 10.

Department of Dermatology, Venereology, and Allergology, University Medical Center, Göttingen, Germany.

View Article and Full-Text PDF

Pityriasis rubra pilaris in skin of color.

Int J Womens Dermatol 2021 Mar 19;7(2):207-208. Epub 2021 Jan 19.

Department of Dermatology and Dermatologic Surgery, Medical University of South Carolina, Charleston, SC, United States.

View Article and Full-Text PDF

Risankizumab for pityriasis rubra pilaris.

Authors:
E Brocco E Laffitte

Clin Exp Dermatol 2021 Apr 29. Epub 2021 Apr 29.

Department of Dermatology, Geneva University Hospital, Geneva, Switzerland.

Pityriasis rubra pilaris (PRP) is a rare dermatological disease which shares similar inflammatory pathways and cytokines activation profile with psoriasis. Hence, in-label psoriasis treatments have recently been used off-label to treat PRP. We report the first case of a PRP patient treated with risankizumab (Skyrizi) with a dramatic skin improvement. Read More

View Article and Full-Text PDF

Pityriasis rubra pilaris post-infection due COVID-19: case report.

Colomb Med (Cali) 2021 Mar 18;52(1):e7014577. Epub 2021 Mar 18.

Universidad San Ignacio de Loyola, Lima, Perú. Universidad San Ignacio de Loyola Universidad San Ignacio de Loyola Lima Peru.

Case Description: 32-month-old boy, IgG positive for SARS-CoV-2, presented to the emergency department with dermatologic lesions.

Clinical Findings: Four days before admission, he presented skin eruptions with redness and pruritus on hands and feet. Generalized papular erythema was evidenced, upper extremities with diffuse erythematosquamous plaques, palmoplantar keratoderma, so he was evaluated by a dermatologist who diagnosed pityriasis rubra pilaris. Read More

View Article and Full-Text PDF

Drug survival of systemic and biologic monotherapy treatments for pityriasis rubra pilaris: A retrospective observational study.

J Am Acad Dermatol 2021 Apr 21. Epub 2021 Apr 21.

Department of Dermatology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.

View Article and Full-Text PDF

Pityriasis rubra pilaris induced by PD-1 inhibitor nivolumab.

Int J Dermatol 2021 Apr 12. Epub 2021 Apr 12.

The Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel.

View Article and Full-Text PDF

[Early onset of methotrexate-associated lymphoproliferative disorder mimicking Hodgkin's lymphoma].

Hautarzt 2021 Apr 1. Epub 2021 Apr 1.

Klinik und Poliklinik für Dermatologie und Venerologie, Universitätsklinikum Hamburg-Eppendorf, Martinistr. 52, 20246, Hamburg, Deutschland.

Long-term methotrexate (MTX) treatment is known to cause MTX-associated lymphoproliferative disorder (MTX-LPD). A 58-year-old woman with psoriasis vulgaris and pityriasis rubra pilaris was treated with a combination of MTX and ustekinumab for 4 months when she developed generalized lymphadenopathy. The initial histopathological analysis indicated Hodgkin's lymphoma; however, assessing the patient's clinical history revealed the diagnosis of MTX-LPD. Read More

View Article and Full-Text PDF

Clinical features and eosinophilia in pityriasis rubra pilaris: A multicenter cohort.

J Am Acad Dermatol 2021 Mar 24. Epub 2021 Mar 24.

Department of Dermatology, Brigham and Women's Hospital, Boston, Massachusetts. Electronic address:

View Article and Full-Text PDF

Response to: 'Successful treatment of refractory extensive pityriasis rubra pilaris with risankizumab'.

Br J Dermatol 2021 Mar 17. Epub 2021 Mar 17.

Dermatology Department, Hospital de Santo António dos Capuchos, Centro Hospitalar Universitário de Lisboa Central, Lisbon, Portugal.

View Article and Full-Text PDF

Pityriasis rubra pilaris: a bibliometric analysis.

Int J Dermatol 2021 Feb 20. Epub 2021 Feb 20.

Division of Dermatology, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, CA, USA.

View Article and Full-Text PDF
February 2021

Case for diagnosis. Atypical Grover's disease.

An Bras Dermatol 2021 Mar-Apr;96(2):234-236. Epub 2021 Feb 2.

Dermopathology Section, Pathology Service, Hospital Clínico Universidad de Chile, Santiago, Chile.

A 55-year-old male presented with an eight-month history of erythematous papules and plaques with demarcated areas of spared skin on his trunk, upper extremities, neck, and face. Grover's disease is a rare, acquired disorder of unknown origin, which is classically characterized by the appearance of erythematous papules on the upper trunk that are usually transient. As in the present case, there are reports of atypical disease, with facial involvement, pityriasis rubra pilaris-like lesions, and a more chronic course. Read More

View Article and Full-Text PDF

[Palmoplantar dermatoses in children].

Hautarzt 2021 Mar 12;72(3):215-224. Epub 2021 Feb 12.

Klinik und Poliklinik für Dermatologie und Allergologie, Klinikum der Universität München LMU, Frauenlobstr. 9-11, 80337, München, Deutschland.

Dermatoses of the hands and feet cover a wide range of skin diseases that can occur in children and adolescents and are a frequent question in dermatological practice. Our synopsis of the most important differential diagnoses and their treatment is intended to provide better orientation for daily practice. A precise and detailed history is essential to establish a diagnosis, followed by clinical examination and specific examination methods. Read More

View Article and Full-Text PDF

Flexural Circumscribed Juvenile Pityriasis Rubra Pilaris: An Unusual Presentation.

Indian J Dermatol 2020 Nov-Dec;65(6):542-543

Department of Skin and VD, Patna Medical College and Hospital, Patna, India. E-mail:

View Article and Full-Text PDF
January 2021

Identification of a pathogenic mutation in a 70-year-old woman with pityriasis rubra pilaris: when genetic diagnosis influences choice of treatment strategy.

BMJ Case Rep 2021 Jan 11;14(1). Epub 2021 Jan 11.

Dermatology and Allergy Center, University Hospital of Odense, Odense, Denmark.

Pityriasis rubra pilaris (PRP) is a rare dermatosis characterised by hyperkeratotic follicular papules, orange-red scaly plaques and palmoplantar keratoderma. The aetiology of the disease is in most cases unclear and treatment can be challenging. Familial cases of PRP may result from pathogenic variants in the caspase recruitment domain family member 14 (CARD14). Read More

View Article and Full-Text PDF
January 2021

The beneficial effect of a PDE4 inhibitor in a patient with juvenile-onset intractable pityriasis rubra pilaris without CARD14 mutation.

Dermatol Ther 2021 01 10;34(1):e14714. Epub 2021 Jan 10.

Department of Dermatology, Osaka University Graduate School of Medicine, Suita, Osaka, Japan.

View Article and Full-Text PDF
January 2021

Follicular Graft Vs Host Reaction: A Rare Presentation.

Indian Dermatol Online J 2020 Nov-Dec;11(6):988-990. Epub 2020 Sep 19.

Department of Dermatology, Armed Forces Medical College, Pune, Maharashtra, India.

Graft versus host disease (GVHD) is a unique entity wherein the donated marrow cells (graft) view the hosts as foreign and attack various body organs. Skin is the most frequently affected organ followed by mucosa, eyes, gastrointestinal, respiratory, musculoskeletal system, and other organs. The incidence of GVHD varies from 25 to 80%. Read More

View Article and Full-Text PDF
September 2020

Acute Postinfection Pityriasis Rubra Pilaris: Excellent Response to Emollients and Topical Corticosteroids.

Actas Dermosifiliogr (Engl Ed) 2020 Dec 8. Epub 2020 Dec 8.

Departamento de Dermatología, Facultad de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile. Electronic address:

View Article and Full-Text PDF
December 2020

The IL-23/IL-17 Pathway in Inflammatory Skin Diseases: From Bench to Bedside.

Front Immunol 2020 17;11:594735. Epub 2020 Nov 17.

Department of Dermatology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.

Interleukin-17 (IL-17) is an essential proinflammatory cytokine, which is mainly secreted by the CD4 helper T cells (Th17 cells) and subsets of innate lymphoid cells. IL-17A is associated with the pathogenesis of inflammatory diseases, including psoriasis, atopic dermatitis, hidradenitis suppurativa, alopecia areata, pityriasis rubra pilaris, pemphigus, and systemic sclerosis. Interleukin-23 (IL-23) plays a pivotal role in stimulating the production of IL-17 by activating the Th17 cells. Read More

View Article and Full-Text PDF
November 2020

Successful treatment of refractory extensive pityriasis rubra pilaris with risankizumab.

Authors:
J Ricar P Cetkovska

Br J Dermatol 2021 05 4;184(5):e148. Epub 2020 Dec 4.

Department of Dermatovenereology, Faculty of Medicine in Pilsen, Charles University, Prague, Czech Republic.

View Article and Full-Text PDF

Secukinumab is an effective and safe treatment for refractory pityriasis rubra pilaris: a case report and literature review.

G Ital Dermatol Venereol 2020 Nov 12. Epub 2020 Nov 12.

Dermatology Clinic of Terni, Università degli Studi di Perugia, Terni, Italy.

View Article and Full-Text PDF
November 2020